GR3034823T3 - Effects of actin filaments on fibrin clot structure and lysis. - Google Patents

Effects of actin filaments on fibrin clot structure and lysis.

Info

Publication number
GR3034823T3
GR3034823T3 GR20000402510T GR20000402510T GR3034823T3 GR 3034823 T3 GR3034823 T3 GR 3034823T3 GR 20000402510 T GR20000402510 T GR 20000402510T GR 20000402510 T GR20000402510 T GR 20000402510T GR 3034823 T3 GR3034823 T3 GR 3034823T3
Authority
GR
Greece
Prior art keywords
actin
lysis
effects
fibrin clot
actin filaments
Prior art date
Application number
GR20000402510T
Other languages
English (en)
Inventor
Paul A Janmey
Jennifer A Lamb
Stuart E Lind
Thomas P Stossel
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of GR3034823T3 publication Critical patent/GR3034823T3/el

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4712—Muscle proteins, e.g. myosin, actin, protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/10—Composition for standardization, calibration, simulation, stabilization, preparation or preservation; processes of use in preparation for chemical testing
    • Y10T436/106664—Blood serum or blood plasma standard or control

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Analytical Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Immobilizing And Processing Of Enzymes And Microorganisms (AREA)
GR20000402510T 1992-08-14 2000-11-10 Effects of actin filaments on fibrin clot structure and lysis. GR3034823T3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/929,203 US5691160A (en) 1992-08-14 1992-08-14 Effects of actin filaments of fibrin clot structure and lysis
PCT/US1993/007584 WO1994004704A1 (en) 1992-08-14 1993-08-13 Effects of actin filaments on fibrin clot structure and lysis

Publications (1)

Publication Number Publication Date
GR3034823T3 true GR3034823T3 (en) 2001-02-28

Family

ID=25457479

Family Applications (1)

Application Number Title Priority Date Filing Date
GR20000402510T GR3034823T3 (en) 1992-08-14 2000-11-10 Effects of actin filaments on fibrin clot structure and lysis.

Country Status (11)

Country Link
US (1) US5691160A (el)
EP (1) EP0655089B1 (el)
JP (1) JPH08500488A (el)
AT (1) ATE197478T1 (el)
CA (1) CA2142121C (el)
DE (1) DE69329652T2 (el)
DK (1) DK0655089T3 (el)
ES (1) ES2151517T3 (el)
GR (1) GR3034823T3 (el)
PT (1) PT655089E (el)
WO (1) WO1994004704A1 (el)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
US6391343B1 (en) 1991-01-15 2002-05-21 Hemosphere, Inc. Fibrinogen-coated particles for therapeutic use
JP2002503254A (ja) 1997-06-05 2002-01-29 ヘモスフィア，インコーポレイテッド フィブリノゲンをコーティングしたミクロスフィア
AU7726598A (en) * 1997-06-05 1998-12-21 Hemosphere, Inc. Modification of platelet action by fibrinogen-coated particles
FR2781055B1 (fr) * 1998-07-09 2000-10-13 Immunotech Sa Reactif et methode pour la permeabilisation et l'identification des erythrocytes
EP1210101A4 (en) * 1999-08-13 2005-10-12 Hemodyne Inc METHOD OF USING BLOOD PLATELET CONTRAST FORCE AND TOTAL BLOOD TUBE ELASTICITY MODULE AS CLINICAL MARKERS
US7301020B2 (en) * 2003-06-19 2007-11-27 Wisconsin Alumni Research Foundation Macrolide analogs and methods for identifying same
US9408891B2 (en) * 2003-11-12 2016-08-09 The Trustees Of The University Of Pennsylvania Methods of using gelsolin to treat or prevent bacterial sepsis
PL1694342T3 (pl) * 2003-11-12 2021-07-05 Trustees Of The University Of Pennsylvania Sposoby zastosowania gelsoliny do leczenia lub zapobiegania posocznicy bakteryjnej
KR101314461B1 (ko) * 2004-05-12 2013-10-07 더 브리검 앤드 우먼즈 하스피털, 인크. 감염 치료를 위한 겔솔린의 용도
GB0507981D0 (en) * 2005-04-20 2005-05-25 Uws Ventures Ltd Method of determining the point at which coagulating blood forms a clot
PL3279663T3 (pl) 2006-03-15 2022-01-10 The Brigham And Women's Hospital, Inc. Zastosowanie gelsoliny do diagnozowania i leczenia chorób zapalnych
JP2009530613A (ja) * 2006-03-15 2009-08-27 ザ・ブリガム・アンド・ウイメンズ・ホスピタル・インコーポレイテッド 多発性硬化症を治療するため、および神経疾患を診断するための、ゲルゾリンの使用
CA3080273C (en) * 2008-01-25 2022-11-22 The General Hospital Corporation Diagnostic and therapeutic uses of gelsolin in renal failure
AU2011303467C1 (en) * 2010-09-15 2017-03-09 Debiopharm International Sa Method for separating target molecules or particles from fibrinogen-containing samples including blood components
KR101416954B1 (ko) * 2012-09-12 2014-07-16 한양대학교 산학협력단 조혈세포 분화 유도 방법

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1988010259A1 (en) * 1987-06-19 1988-12-29 Syracuse University Cytochalasin purification methods and compositions
US5326749A (en) * 1989-11-20 1994-07-05 Nobuto Yamamoto Macrophage activating factor from vitamin D binding protein
US5177002A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated human vitamin D binding protein to a potent macrophage activating factor
US5177001A (en) * 1989-11-20 1993-01-05 Nobuto Yamamoto In vitro enzymatic conversion of glycosylated mammalian vitamin D-binding protein to a potent macrophage activating factor
US5464817A (en) * 1990-04-11 1995-11-07 Brigham And Women's Hospital Method for reducing the viscosity of pathological mucoid airway contents in the respiratory tract comprising administering actin-binding compounds with or without DNASE I
CA2080462C (en) * 1990-04-11 2004-10-26 Thomas P. Stossel Therapeutic uses of actin-binding compounds

Also Published As

Publication number Publication date
CA2142121C (en) 2003-09-09
EP0655089B1 (en) 2000-11-08
DK0655089T3 (da) 2001-02-12
DE69329652D1 (de) 2000-12-14
DE69329652T2 (de) 2001-06-13
WO1994004704A1 (en) 1994-03-03
ATE197478T1 (de) 2000-11-11
ES2151517T3 (es) 2001-01-01
JPH08500488A (ja) 1996-01-23
PT655089E (pt) 2001-04-30
US5691160A (en) 1997-11-25
EP0655089A1 (en) 1995-05-31
CA2142121A1 (en) 1994-03-03
EP0655089A4 (en) 1997-04-02

Similar Documents

Publication Publication Date Title
GR3034823T3 (en) Effects of actin filaments on fibrin clot structure and lysis.
ES8501979A1 (es) Procedimiento para preparar un concentrado de factor antihemofilico
EP0853121A3 (en) Human DNase
ES2179077T3 (es) Acido glutamico decarboxilasa clonada.
CA2054699A1 (en) Growth of vascular endothelial cell growth factor and dna encoding same
DE69002395D1 (de) N-terminale fragmente von menschliches serumalbumin enthaltenden fusionsproteinen.
CA2068204A1 (en) Latency associated peptides and uses therefor
DK31088A (da) Blodkoaguleringsnedsaettende peptidderivater
ZA88634B (en) Precursor protein of apc polypeptide,dna coding for this,and diagnostic use of the dna and of the protein
DE68912485D1 (de) Kryogene und mechanische Gefrierkombination.
CA2080462A1 (en) Therapeutic uses of actin-binding compounds
GR900100621A (en) Polypeptide analogs of apolipoprotein e diagnostic systems and methods using the analogs
JPS6463596A (en) Novel peptide having activity inhibiting platelet coagulation and adaptation thereof to medical treatment
AU2021195A (en) Determination of an individual's inflammation index from whole blood fibrinogen and hematocrit or hemoglobin measurements
IL76441A0 (en) Blood coagulation inhibiting proteins and their preparation
DE3686295D1 (de) Reinigung von koagulationsfaktoren des blutes und von anderen proteinen auf sulfatierten nicht carbohydratierten matrizen.
NZ220526A (en) Peptide which inhibits binding of von willebrand factor to heparin, platelets and collagen
EP0959682A4 (en) THERAPEUTIC AND DIAGNOSTIC APPLICATIONS OF LAMININ AND LAMININ-DERIVED PROTEIN FRAGMENTS
ZA886273B (en) Novel hiv proteins and peptides useful in the diagnosis,prophylaxis or therapy of aids
CA2154080A1 (en) Novel anticoagulant cofactor activity
FR2694296B1 (fr) Peptides inhibant l'activité des protéines ras, préparation et utilisation.
MC1884A1 (fr) Variants de l'hirudine,leur utilisation et leur preparation
IT8921128A0 (it) Metodo per la determinazione della attivita' funzionale della proteina s nel plasma umano.
NO892269L (no) Ikke-hyperglykosylerte hepatitt b-virus-proteiner samt ekspresjons-"kassetter" og fremgangsmaate for fremstilling avproteinene.
NZ230327A (en) Synergistic combination of t-pa and activated protein c (apc)

Legal Events

Date Code Title Description
ML Lapse due to non-payment of fees